1009601-82-4

Upstream product

• 1009601-76-6 2-Isopropyl-7-methoxy-pyrazolo[1,5-a]pyridine-4-carbaldehyde 
• 1009601-74-4 4-Hydroxymethyl-2-isopropyl-7-methoxypyrazolo[1,5-a]pyridine 
• 1009601-72-2 4-Hydroxymethyl-2-isopropyl-7-methoxypyrazolo[1,5-a]pyridine-3-carboxylic acid 
• 1009601-71-1 4-Hydroxymethyl-2-isopropyl-7-methoxypyrazolo[1,5-a]pyridine-3-carboxylic acid benzyl ester 
• 100-02-7 4-nitro-phenol 
• 1009601-79-9 2-Isopropyl-7-methoxypyrazolo[1,5-a]pyridine-4-carboxylic acid 

Relevant academic research and scientific papers

Phosphodiesterase inhibitors. Part 6: Design, synthesis, and structure-activity relationships of PDE4-inhibitory pyrazolo[1,5-a]pyridines with anti-inflammatory activity

We previously identified KCA-1490 [(-)-6-(7-methoxy-2-trifluoromethyl- pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydro-3-(2H)-pyridazinone], a dual PDE3/4 inhibitor. In the present study, we found highly potent selective PDE4 inhibitors derived from the structure of KCA-1490. Among them, N-(3,5-dichloropyridin-4-yl)-7-methoxy-2-(trifluoromethyl)pyrazolo[1,5-a] pyridine-4-carboxamide (2a) had good anti-inflammatory effects in an animal model.

PYRAZOLOPYRIDINE CARBOXAMIDE DERIVATIVE AND PHOSPHODIESTERASE (PDE) INHIBITOR COMPRISING THE DERIVATIVE

A novel pyrazolopyridine carboxamide derivative is provided that is useful as a pharmaceutical drug having phosphodiesterase inhibitory activity. The pyrazolopyridine carboxamide derivative is represented by the following general formula (1): (Example: 2-